Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography.

Patel R, Janoudi A, Vedre A, Aziz K, Tamhane U, Rubinstein J, Abela OG, Berger K, Abela GS.

Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2007-14. doi: 10.1161/ATVBAHA.111.226167. Epub 2011 Aug 4.

2.

Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography.

Zhang MD, Zhao XC, Zhang YH, Yan YF, Wang ZM, Lv SZ, Zhao QM.

Cardiovasc Ther. 2015 Jun;33(3):118-26. doi: 10.1111/1755-5922.12119.

PMID:
25825053
3.

Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe.

Habara M, Nasu K, Terashima M, Ko E, Yokota D, Ito T, Kurita T, Teramoto T, Kimura M, Kinoshita Y, Tsuchikane E, Asakura Y, Matsubara T, Suzuki T.

Am J Cardiol. 2014 Feb 15;113(4):580-7. doi: 10.1016/j.amjcard.2013.10.038. Epub 2013 Nov 22.

PMID:
24388622
4.

Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography.

Aziz K, Berger K, Claycombe K, Huang R, Patel R, Abela GS.

Circulation. 2008 Apr 22;117(16):2061-70. doi: 10.1161/CIRCULATIONAHA.106.652313. Epub 2008 Apr 7.

5.

Imaging of atherosclerotic aorta of rabbit model by detection of plaque inflammation with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Zhao QM, Feng TT, Zhao X, Xu ZM, Liu Y, Li DP, Li LQ, Su G, Zhang XX.

Chin Med J (Engl). 2011 Mar;124(6):911-7.

PMID:
21518602
6.

Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Fayad ZA, Mani V, Woodward M, Kallend D, Bansilal S, Pozza J, Burgess T, Fuster V, Rudd JH, Tawakol A, Farkouh ME.

Am Heart J. 2011 Aug;162(2):214-221.e2. doi: 10.1016/j.ahj.2011.05.006.

7.

Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden.

Bogiatzi C, Spence JD.

Stroke. 2012 Apr;43(4):1153-5. doi: 10.1161/STROKEAHA.111.640789. Epub 2012 Jan 5.

8.

Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography.

Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ.

J Nucl Cardiol. 2005 May-Jun;12(3):294-301.

PMID:
15944534
9.

Arterial wall cholesterol content is a predictor of development and severity of arterial thrombosis.

Ma H, Aziz KS, Huang R, Abela GS.

J Thromb Thrombolysis. 2006 Aug;22(1):5-11.

PMID:
16786227
10.

Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model.

Abela GS, Picon PD, Friedl SE, Gebara OC, Miyamoto A, Federman M, Tofler GH, Muller JE.

Circulation. 1995 Feb 1;91(3):776-84.

11.

Pravastatin inhibits plaque rupture and subsequent thrombus formation in atherosclerotic rabbits with hyperlipidemia.

Wu G, Xie Q, Xu L, Jiang H, Huang Z, Huang C.

Chem Pharm Bull (Tokyo). 2013;61(2):121-4. Epub 2012 Dec 3.

12.

Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.

Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D.

Int Angiol. 2010 Dec;29(6):514-24.

PMID:
21173733
13.

Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.

Millon A, Dickson SD, Klink A, Izquierdo-Garcia D, Bini J, Lancelot E, Ballet S, Robert P, Mateo de Castro J, Corot C, Fayad ZA.

Atherosclerosis. 2013 Jun;228(2):339-45. doi: 10.1016/j.atherosclerosis.2013.03.019. Epub 2013 Mar 26.

14.

Detection of vulnerable atherosclerotic plaque and prediction of thrombosis events in a rabbit model using 18F-FDG -PET/CT.

Zhao QM, Zhao X, Feng TT, Zhang MD, Zhuang XC, Zhao XC, Li LQ, Li DP, Liu Y.

PLoS One. 2013 Apr 17;8(4):e61140. doi: 10.1371/journal.pone.0061140. Print 2013.

15.

Arterial (18)F-fluorodeoxyglucose uptake reflects balloon catheter-induced thrombus formation and tissue factor expression via nuclear factor-κB in rabbit atherosclerotic lesions.

Yamashita A, Zhao Y, Zhao S, Matsuura Y, Sugita C, Iwakiri T, Okuyama N, Ohe K, Koshimoto C, Kawai K, Tamaki N, Kuge Y, Asada Y.

Circ J. 2013;77(10):2626-35. Epub 2013 Jul 6.

16.

Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology.

Hyafil F, Cornily JC, Rudd JH, Machac J, Feldman LJ, Fayad ZA.

J Nucl Med. 2009 Jun;50(6):959-65. doi: 10.2967/jnumed.108.060749. Epub 2009 May 14.

17.

Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation.

Abela GS.

J Clin Lipidol. 2010 May-Jun;4(3):156-64. doi: 10.1016/j.jacl.2010.03.003. Epub 2010 Mar 16. Review.

PMID:
21122648
18.
19.

Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.

Hiro T, Hirayama A, Ueda Y, Komatsu S, Matsuoka H, Takayama T, Ishihara M, Hayashi T, Saito S, Kodama K; ZIPANGU investigators.

J Cardiol. 2014 Dec;64(6):501-7. doi: 10.1016/j.jjcc.2014.02.026. Epub 2014 Apr 13.

20.

Effects of ezetimibe on atherosclerosis in preclinical models.

Davis HR Jr, Lowe RS, Neff DR.

Atherosclerosis. 2011 Apr;215(2):266-78. doi: 10.1016/j.atherosclerosis.2011.02.010. Epub 2011 Feb 17. Review.

PMID:
21397230

Supplemental Content

Support Center